No black box warning on record for Nateglinide

As of the latest FDA labeling reviewed, Nateglinide (NATEGLINIDE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Nateglinide medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hypoglycemia: Nateglinide may cause hypoglycemia. Administer before meals to reduce the risk of hypoglycemia. Skip the scheduled dose of nateglinide if a meal is skipped to reduce the risk of hypoglycemia. (5.1) Macrovascular Outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with nateglinide. (5.2) 5.1 Hypoglyc

No black box warning on record for Nateglinide

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hypoglycemia: Nateglinide may cause hypoglycemia. Administer before meals to reduce the risk of hypoglycemia. Skip the scheduled dose of nateglinide if a meal is skipped to reduce the risk of hypoglycemia. (5.1) Macrovascular Outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with nateglinide. (5.2) 5.1 Hypoglyc

Nateglinide Black Box Warning

No black box warning on record for Nateglinide

Other warnings & precautions

Nateglinide Black Box Warning

No black box warning on record for Nateglinide

Other warnings & precautions